ICAD (Intracranial Atherosclerotic Disease) Pathology Market Trends and Forecast
The future of the global ICAD (intracranial atherosclerotic disease) pathology market looks promising with opportunities in the hospital and clinic markets. The global ICAD (intracranial atherosclerotic disease) pathology market is expected to grow with a CAGR of 8.5% from 2025 to 2031. The major drivers for this market are the rising prevalence of cardiovascular diseases and the growing awareness and early detection efforts.
• Lucintel forecasts that, within the type category, stent is expected to witness higher growth over the forecast period.
• Within the application category, the hospital is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the ICAD (Intracranial Atherosclerotic Disease) Pathology Market
The global ICAD (Intracranial Atherosclerotic Disease) pathology market is in the midst of a paradigm shift, with a number of emerging trends that hold the key to transforming diagnosis, treatment, and management of patients. The trends are fueled by an increased understanding of ICAD pathophysiology, innovation in medical technology, and increased focus on personalized medicine. From advanced imaging technology depicting plaque composition to genetic data guiding risk stratification, the industry is shifting toward more accurate, less aggressive, and more proactive strategies to manage this difficult cerebrovascular illness. These new technologies are important for minimizing the incidence of stroke recurrence as well as enhancing long-term neurological results.
• High-Resolution Vessel Wall Imaging (HR-VWI): A significant trend is the increasing adoption and refinement of high-resolution vessel wall imaging techniques, particularly using MRI. HR-VWI allows for direct visualization of the intracranial arterial wall, enabling the characterization of plaque morphology, composition, and inflammation, which traditional lumen-based imaging cannot provide. This level of detail is what distinguishes ICAD from other vasculopathies and detects vulnerable plaques at greater risk of rupture or embolization. Its effect is a more precise diagnosis, improved risk stratification, and personalized treatment plans according to plaque characteristics.
• Precision Medicine Strategies: The industry is moving toward precision medicine, utilizing unique patient information, such as genetic maps, imaging results, and clinical risk determinants, to personalize diagnostic and therapeutic plans for ICAD. This includes finding particular biomarkers or genetics related to ICAD vulnerability or development. Its effect is a shift from one-size-fits-all treatment towards individualized treatment plans, which can translate into more efficient interventions and fewer adverse events. It enables personalized risk stratification and therapy targeting, enhancing patient outcomes.
• Machine Learning and Artificial Intelligence in Diagnosis: Machine learning and artificial intelligence algorithms are being used more to study huge volumes of medical imaging data, clinical data, and genetic data pertaining to ICAD. Such AI solutions may help automate plaque detection, quantitative stenosis analysis, stroke risk prediction, and determination of the best treatment strategy. The benefit is greater diagnostic efficiency, improved precision, and the ability to detect faint patterns not visible to the naked eye. This results in earlier detection, better risk stratification, and more effective clinical decisions.
• Sophisticated Endovascular Interventions: The creation of more advanced and safer endovascular devices and methods is a key upcoming trend. These products comprise new intracranial stents with enhanced designs, drug-eluting balloons, and enhanced guidewire technology for more precise navigation through challenging intracranial anatomy. These technologies seek to enhance the revascularization rates, minimize periprocedural complications, and maximize long-term patency of the targeted vessels. The effect is an expansion of therapeutic choices for ICAD patients, especially those resistant to medical treatment, presenting less invasive options to open surgery and enhancing clinical results.
• Biomarker Discovery and Validation: There is increased interest in the discovery and validation of new circulating or imaging biomarkers that can assist in the diagnosis, prognosis, and monitoring of ICAD. These may encompass inflammatory markers, genetic markers, or certain lipid profiles. The aim is to offer non-invasive early detection tools and monitor disease progression or treatment response. The significance is the promise of early intervention, enhanced risk stratification, and creation of novel therapeutic targets. The trend supports a more anticipatory management of ICAD and stroke prevention.
These new trends collectively redefine the worldwide ICAD (Intracranial Atherosclerotic Disease) pathology market by propelling it towards a more advanced, personalized, and proactive disease management. The combination of high-resolution imaging, precision medicine, and AI is improving diagnostic quality and risk stratification, whereas sophisticated endovascular interventions and biomarker discovery are expanding treatment opportunities and allowing intervention earlier. These advances are key to enhanced patient outcomes, decreased stroke burden, and better understanding of ICAD pathophysiology.
Recent Development in the ICAD (Intracranial Atherosclerotic Disease) Pathology Market
The global ICAD (Intracranial Atherosclerotic Disease) pathology market has witnessed various recent developments fueled by ongoing innovation in medical technology as well as increasing insight into the diseaseÄX%$%Xs complexity. These trends are improving diagnostic accuracy, broadening therapeutic options, and refining patient risk stratification. The trend is toward increasingly non-invasive diagnostic modalities, individualized treatment regimens, and the use of sophisticated computational techniques to more fully understand ICAD. These advances are critical to minimizing the large burden of stroke for ICAD and optimizing long-term neurological outcomes for individuals with ICAD worldwide.
• Improved High-Resolution Vessel Wall Imaging (HR-VWI) Capabilities: Over the past few years, HR-VWI methods have significantly improved, especially with 3T and 7T MRI machines. These advances provide never-before-seen visualization of the intracranial arterial wall and allow for precise evaluation of plaque burden, morphology, and inflammation. The consequence is improved differentiation of ICAD from other intracranial vasculopathies and detection of high-risk plaques, resulting in more accurate diagnoses and more informed decision-making about medical and interventional therapies.
• Artificial Intelligence Integration for Image Analysis: One major recent advance has been the growing integration of machine learning and artificial intelligence algorithms into ICAD imaging data analysis. AI software can automate vessel wall segmentation, measure stenosis, detect plaque components, and estimate stroke risk based on imaging features. The effect is enhanced diagnostic effectiveness, decreased inter-observer variation in image interpretation, and the ability to reveal faint patterns that aid in early detection and risk stratification, thereby speeding up diagnostic procedures and improving accuracy.
• Novel Intracranial Stents and Drug-Eluting Balloons: Some recent developments in endovascular therapy involve the creation and introduction of next-generation intracranial stents and drug-eluting balloons specially tailored to the challenging anatomy of intracranial arteries. These devices hope to enhance navigability, minimize periprocedural complications, and avert restenosis. The effect is to increase safe and effective treatment for patients with symptomatic or severe ICAD that is unresponsive to medical therapy, providing better revascularization rates and a lower risk of recurrent stroke.
• Genetic and Biomarker Discovery Studies: Research has accelerated in the discovery of genetic predispositions and new biomarkers linked to ICAD susceptibility, development, and recurrence of stroke. Investigations are investigating the functions of individual genes, inflammatory markers, and lipid profiles. The result is an enhanced understanding of ICAD pathophysiology, resulting in improved risk stratification tools and potential for the development of focused pharmacologic therapies. This study propels the field towards more personalized prevention and therapy approaches on the basis of the individual patientÄX%$%Xs characteristics.
• Greater Emphasis on Pathological-Radiological Correlation Studies: Recent advances point towards a greater focus on correlating pathological findings from post-mortem or surgical material with high-resolution in vivo imaging. This is directed towards validating imaging biomarkers and better grasping the underlying histological characteristics of ICAD plaques. The implications are enhanced diagnostic precision of non-invasive imaging methods and greater insight into the natural history and path mechanisms of ICAD-associated stroke. This association is crucial for optimizing diagnostic criteria and creating more precise treatment methods.
These new advances are having a profound effect on the worldwide ICAD (Intracranial Atherosclerotic Disease) pathology market by bringing an era of increased accuracy in diagnosis, individualized risk assessment, and sophisticated therapeutic management. The convergence of high-resolution imaging, AI, innovative devices, and genetic studies is revolutionizing the understanding and treatment of ICAD. These innovations are essential in countering the catastrophic effects of ICAD-stroke and enhancing the quality of life of patients globally.
Strategic Growth Opportunities in the ICAD (Intracranial Atherosclerotic Disease) Pathology Market
The global ICAD (Intracranial Atherosclerotic Disease) pathology market has various strategic growth opportunities backed by the mounting burden of stroke and ongoing developments in medical science. The growth opportunities are centered on improving diagnostic accuracy, broadening therapeutic approaches, and enhancing patient management in different settings of healthcare. Building on these areas entails creating cutting-edge technologies, promoting collaborations, and solving unmet clinical needs to deliver better and more accessible solutions to patients dealing with ICAD. These avenues are pivotal in decreasing the risk of stroke as well as enhancing long-term neurological outcomes.
• Early Diagnosis and Risk Stratification: One major growth area is the creation and marketing of sophisticated non-invasive diagnostic equipment for earlier detection of ICAD, particularly in asymptomatic subjects or those with mild disease. This encompasses sensitive imaging modalities and new biomarker assays to detect high-risk plaque characteristics. The application would shift from treatment after stroke to prevention before stroke. By recognizing patients with high risk early, clinicians are able to institute intense medical management and lifestyle changes, which result in a dramatic reduction in the occurrence of ICAD-related stroke and a better prognosis for the patient.
• Creation of Targeted Therapeutics: There is a tremendous opportunity for growth in the development of new pharmacologic agents with specific activity against the primary pathological processes of ICAD, rather than available antiplatelet and statin therapy. This also encompasses drugs that stabilize unstable plaques, decrease inflammation, or induce plaque regression. The use is aimed at personalized medicine, where the treatments are adapted to individual plaque types or patient genetic profiles. Success here would transform ICAD management by providing less invasive yet more effective treatment strategies with improved long-term outcomes.
• Expansion of Endovascular Intervention Capability: Although endovascular therapy for ICAD has had variable success, there is unequivocal room for expansion in improving and enlarging its use for well-chosen patients. This includes creating next-generation intracranial stents, drug-eluting balloons, and optimized procedures that reduce periprocedural hazards. Its use is to offer effective revascularization in symptomatic, high-grade stenoses, especially in those who do not respond to aggressive medical therapy. Investment in training programs for neurointerventional and the creation of safer, more effective devices will be the key to unlocking this opportunity.
• Integration with Artificial Intelligence and Digital Health Platforms: The integration of ICAD pathology data with analytical tools based on AI and wider digital health platforms is a strategic growth opportunity. These consist of AI for automating the analysis of images, risk prediction, and clinical decision support systems. The app will seek to automate diagnostic workflows, enhance diagnostic quality, and support remote consultation and patient monitoring. Companies can concentrate on building interoperable platforms that integrate imaging data with electronic health records, further supporting data-driven decision-making and enhancing overall ICAD management efficiency.
• Global Outreach and Education in High-Prevalence Regions: Due to the disproportionate prevalence of ICAD in some Asian and African populations, high growth potential lies in increasing diagnostic and therapeutic solutions in these markets. This includes creating low-cost imaging technologies, offering training to healthcare workers, and educating the general public regarding ICAD risk factors and symptoms. The solution targets unmet needs in these high-burden geographies through local solutions and education programs. This not only increases market share but also supports international efforts in public health to decrease stroke occurrence.
These strategic growth opportunities have the potential to make a substantial difference in the global ICAD (Intracranial Atherosclerotic Disease) pathology market by propelling innovation and increasing access to innovative diagnostic and therapeutic solutions. Targeted therapy and early diagnosis hold the key to revolutionizing patient outcomes. The widening of endovascular capabilities and the addition of AI and digital health will expand treatment possibilities and workflow efficiency. In addition, global extension in high-prevalence areas will bridge unmet needs, ultimately lowering the global burden of ICAD-related stroke.
ICAD (Intracranial Atherosclerotic Disease) Pathology Market Driver and Challenges
The ICAD (Intracranial Atherosclerotic Disease) pathology market is influenced by a multifaceted interaction of competing technological, economic, and regulatory factors. Its path is driven by increasing global stroke burden, especially among Asian populations, and noteworthy advances in neuroimaging and interventional treatments. Nevertheless, the market also has certain stiff challenges that pertain to the intricacy of diagnosis, the invasive nature of some tests, and the necessity for uniform treatment protocols. The appreciation of these complex drivers and challenges is essential for stakeholders to operate the market successfully and deliver better patient outcomes.
The factors responsible for driving the icad (intracranial atherosclerotic disease) pathology market include:
1. High Global Prevalence of ICAD-Related Stroke: The major driver includes the high and increasing global prevalence of ICAD, which is a major cause of ischemic stroke. This is especially notable in Asian populations, where ICAD contributes to a large percentage of strokes. The growing population of patients with ICAD generates a constant and pressing need for efficient diagnostic, prognostic, and therapeutic approaches to reduce stroke risk and enhance neurological recovery. This demographic situation naturally fuels research and development in the ICAD (Intracranial Atherosclerotic Disease) pathology market.
2. Neuroimaging Technology Advances: Major advances in neuroimaging technologies, including vessel wall MRI at high resolution, CT angiography, and perfusion imaging, are propelling the market. These modalities offer more detailed information on plaque morphology, lesion activity, and hemodynamic effect, extending beyond mere luminal stenosis measurement. The precise characterization of ICAD lesions by these capabilities allows for more exact diagnosis, improved risk stratification, and personalization of treatment decisions, rendering these diagnostic tools invaluable in contemporary stroke management.
3. Growing Awareness and Early Diagnosis Programs: Heightened awareness among the public and healthcare professionals of stroke risk factors and the necessity for early diagnosis in ICAD is a major driver. Medical education and public health programs encourage screening and early intervention. With improving diagnostic technology, more ICAD cases are being diagnosed, generating growing demand for pathology market solutions ranging from biomarkers and imaging to interventional devices and post-stroke rehabilitation.
4. Minimally Invasive Endovascular Therapies Development: Continued innovation in the development of less risky and more efficient minimally invasive endovascular treatments, such as intracranial stenting and drug-eluting balloons, is fueling market growth. These innovations provide less invasive therapies than open surgery, which are acceptable to both clinicians and patients. Advances in device design, steerability, and complication rates are enhancing clinician confidence and uptake of these therapeutic treatments for carefully selected ICAD patients, fueling market growth.
5. Increasing Investment in Research and Development: Major investments by pharmaceutical firms, medical device companies, and research institutes into learning about ICAD pathophysiology, discovering new biomarkers, and creating new diagnostic and therapeutic strategies are a major driving factor. This investment spurs innovation, which results in the launch of innovative technologies and therapies that enhance patient care. Joint research endeavors between academia and industry are speeding up the rate of discovery in the ICAD (Intracranial Atherosclerotic Disease) pathology market.
Challenges in the icad (intracranial atherosclerotic disease) pathology market are:
1. Heterogeneity and Complexity of ICAD Pathology: One of the greatest challenges is the inherent heterogeneity and complexity of ICAD pathophysiology. ICAD may present with varying plaque morphology, stroke mechanisms (e.g., local thrombosis, artery-to-artery embolism, hypoperfusion), and co-morbid conditions. Such heterogeneity renders standardization of diagnosis, risk stratification, and treatment guidelines difficult, as any one-size-fits-all strategy is bound to fail, resulting in the inability to perform large-scale, definitive clinical trials.
2. Excessive Cost of New Diagnostic and Therapeutic Instruments: Advanced neuroimaging modalities and interventional devices employed in ICAD pathology tend to be costly. This may act as a major economic deterrent towards uptake, especially in developing nations or in resource-constrained healthcare systems. The cost of equipment, maintenance, and specialized training may restrict the use of state-of-the-art ICAD management, generating inequalities in patient care and hindering market penetration in some areas.
3. Periprocedural Risk of Complications during Interventions: Even with advancements, periprocedural complications of percutaneous intervention for ICAD, like stenting, pose a risk of stroke or hemorrhage. The fragile nature of intracranial arteries and invasive procedure risks may restrict their more widespread use and endorsement, particularly following the inconclusive outcome of initial trials like SAMMPRIS. Balancing the possible advantages of revascularization with these risks continues to be a major clinical and market challenge, influencing treatment guidelines and patient selection.
In summary, the ICAD (Intracranial Atherosclerotic Disease) pathology market is powered mainly by the high incidence of ICAD-related stroke, significant advances in neuroimaging, heightened awareness with early diagnosis, ongoing innovation with minimally invasive endovascular therapies, and considerable investments in research and development. Nevertheless, the market is confronted with serious challenges from the multifaceted and heterogeneous nature of ICAD itself, the extremely high upfront costs of advanced diagnostic and therapeutic technology, and periprocedural risks of complications inherent to interventional treatments. Mastering these drivers and challenges will require ongoing innovation in therapeutics and diagnostics, pricing models, and strong clinical evidence to support maximum patient care and long-term market growth.
List of ICAD (Intracranial Atherosclerotic Disease) Pathology Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ICAD (intracranial atherosclerotic disease) pathology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ICAD (intracranial atherosclerotic disease) pathology companies profiled in this report include-
• Stryker
• Balt
• TERUMO
• MicroPort
• Acandis
ICAD (Intracranial Atherosclerotic Disease) Pathology Market by Segment
The study includes a forecast for the global ICAD (intracranial atherosclerotic disease) pathology market by type, application, and region.
ICAD (Intracranial Atherosclerotic Disease) Pathology Market by Type [Value from 2019 to 2031]:
• Stent
• PTA Balloon
ICAD (Intracranial Atherosclerotic Disease) Pathology Market by Application [Value from 2019 to 2031]:
• Hospitals
• Clinics
• Other
ICAD (Intracranial Atherosclerotic Disease) Pathology Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the ICAD (Intracranial Atherosclerotic Disease) Pathology Market
ICAD (Intracranial Atherosclerotic Disease) pathology market is a major contributor to ischemic stroke globally, with high incidences among Asian populations. The ICAD (Intracranial Atherosclerotic Disease) pathology market entails the diagnosis, monitoring, and treatment of this disease, and identification of the build-up of plaque and narrowing of the cerebral arteries inside the skull. The recent advancements are promoted by advances in neuroimaging, genetics, and therapeutic treatments to enhance early detection, risk stratification, and customized treatment options. The market is changing to incorporate non-invasive diagnostic methods and innovative interventional treatments to improve patient outcomes while minimizing the stroke burden.
• United States: The United States ICAD (Intracranial Atherosclerotic Disease) pathology market is witnessing the development of high-resolution vessel wall imaging (HR-VWI) with MRI and CT angiography for more accurate plaque characterization. There is growing research in discovering new biomarkers and genetic susceptibility for ICAD with the goal of personalized medicine. Advances in minimally invasive endovascular treatments, such as newer stents and drug-eluting balloons, are also fueling the market. Further, artificial intelligence and machine learning are being applied increasingly to process complex medical data for early detection and better treatment planning.
• China: China is a large market for ICAD because the East Asian population is highly prevalent with the condition. Current advances include large-scale studies of the genetic underpinnings of ICAD in Chinese populations, involving genome sequencing to detect rare genomic variants. High-resolution vessel wall MRI is emphasized to distinguish ICAD from other intracranial arterial illnesses. The market also witnesses the evolution and integration of advanced imaging methods for improved characterization of plaque morphology and hemodynamic effects to enhance diagnostic accuracy and inform treatment.
• Germany: In Germany, the ICAD (Intracranial Atherosclerotic Disease) pathology market is fueled by compliance with European Stroke Organization guidelines with an emphasis on evidence-based recommendations for management. Recent advances involve greater research into the best detection approaches for asymptomatic ICAD and acute large vessel occlusion ischemic stroke caused by ICAD. There is emphasis on high-resolution imaging and detailed examination of ICAD and associated conditions. The market also witnesses a hesitant but rising interest in sophisticated endovascular methods, with special focus on long-term outcomes and patient safety, frequently based on observational studies and professional consensus.
• India: The Indian ICAD (Intracranial Atherosclerotic Disease) pathology market is dominated by a high prevalence of stroke from ICAD. Recent trends involve the rising application of non-invasive methods such as transcranial Doppler (TCD) and transcranial color-coded duplex sonography (TCCD) for economical evaluation and monitoring of ICAD. Research is also shifting towards understanding ethnic and racial differences in prevalence, severity, and pathogenesis, keeping in view the heterogeneity of risk factor profiles in the Indian population. The market is putting emphasis on enhancing diagnostic accessibility and effective management approaches for preventing stroke.
• Japan: The Japanese ICAD (Intracranial Atherosclerotic Disease) pathology market is very sophisticated with a keen focus on advanced imaging technologies and interventional therapies. New trends are the increasing use of intracranial stenting procedures due to rising ICAD incidence and greater awareness of stroke. The national health insurance system has begun covering intracranial stenting, which will help increase procedure volumes. Studies are also underway to elucidate genetic susceptibilities, including the RNF213 gene, and refine treatment approaches by plaque type and hemodynamic compromise for better patient outcomes.
Features of the Global ICAD (Intracranial Atherosclerotic Disease) Pathology Market
Market Size Estimates: ICAD (intracranial atherosclerotic disease) pathology market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: ICAD (intracranial atherosclerotic disease) pathology market size by types, applications, and region in terms of value ($B).
Regional Analysis: ICAD (intracranial atherosclerotic disease) pathology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the ICAD (intracranial atherosclerotic disease) pathology market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ICAD (intracranial atherosclerotic disease) pathology market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for ICAD (intracranial atherosclerotic disease) pathology market?
Answer: The global ICAD (intracranial atherosclerotic disease) pathology market is expected to grow with a CAGR of 8.5% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the ICAD (intracranial atherosclerotic disease) pathology market?
Answer: The major drivers for this market are the rising prevalence of cardiovascular diseases and the growing awareness and early detection efforts.
Q3. What are the major segments for ICAD (intracranial atherosclerotic disease) pathology market?
Answer: The future of the ICAD (intracranial atherosclerotic disease) pathology market looks promising with opportunities in the hospital and clinic markets.
Q4. Who are the key ICAD (intracranial atherosclerotic disease) pathology market companies?
Answer: Some of the key ICAD (intracranial atherosclerotic disease) pathology companies are as follows:
• Stryker
• Balt
• TERUMO
• MicroPort
• Acandis
Q5. Which ICAD (intracranial atherosclerotic disease) pathology market segment will be the largest in future?
Answer: Lucintel forecasts that, within the type category, stent is expected to witness higher growth over the forecast period.
Q6. In ICAD (intracranial atherosclerotic disease) pathology market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, North America is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the ICAD (intracranial atherosclerotic disease) pathology market by type (stent and PTA balloon), application (hospitals, clinics, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to ICAD (Intracranial Atherosclerotic Disease) Pathology Market, ICAD (Intracranial Atherosclerotic Disease) Pathology Market Size, ICAD (Intracranial Atherosclerotic Disease) Pathology Market Growth, ICAD (Intracranial Atherosclerotic Disease) Pathology Market Analysis, ICAD (Intracranial Atherosclerotic Disease) Pathology Market Report, ICAD (Intracranial Atherosclerotic Disease) Pathology Market Share, ICAD (Intracranial Atherosclerotic Disease) Pathology Market Trends, ICAD (Intracranial Atherosclerotic Disease) Pathology Market Forecast, ICAD (Intracranial Atherosclerotic Disease) Pathology Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.